Synthetic gene circuits that selectively target RAS-driven cancers

Area of Science:

• Oncology
• Synthetic Biology
• Molecular Biology

Background:

• Mutated rat sarcoma (RAS) is a prevalent oncogene in human cancers, driving tumor growth.
• Current RAS inhibitors have limitations, including specificity for KRAS^G12C mutations and acquired resistance.
• Synthetic gene circuits offer a potential strategy for targeted cancer therapy by sensing and responding to cancer-specific signals.

Purpose of the Study:

• To develop highly selective synthetic gene circuits for targeting mutated RAS oncogenes.
• To engineer gene circuits that can integrate multiple RAS mutation signals for enhanced specificity.
• To demonstrate the therapeutic potential of these circuits in RAS-driven cancers.

Main Methods:

• Designed and implemented modular synthetic gene circuits incorporating multiple RAS sensors.
• Utilized computational modeling to optimize circuit component interactions and output expression.
• Adapted circuits for cell-line-specific performance to maximize selectivity and fine-tune expression.
• Linked circuits to the expression of a therapeutic protein for cancer cell killing.

Main Results:

• Achieved unprecedented selectivity in expressing output proteins in cells with mutated RAS.
• Demonstrated successful targeting of various RAS-driven cancer cell lines.
• Validated the therapeutic potential by inducing robust killing of cancer cells with mutated RAS.
• Showcased cell-line-specific adaptation for optimized circuit performance.

Conclusions:

• Synthetic gene circuits represent a promising novel therapeutic strategy for RAS-driven cancers.
• Combining multiple RAS sensors significantly enhances cancer cell selectivity.
• This approach advances the application of synthetic biology in oncology for targeted cancer therapies.